Northwest & Ethical Investments L.P. Has $637,000 Stock Position in Moderna, Inc. $MRNA

Key Points

• Northwest & Ethical Investments L.P. cut its stake in Moderna by 48.3% during the first quarter, selling 21,004 shares and leaving them with 22,462 shares valued at $637,000.
• Institutional investors currently own 75.33% of Moderna's stock, with notable stake increases from firms like Itau Unibanco and Deseret Mutual Benefit Administrators.
• Moderna reported earnings of ($2.13) per share for the last quarter, beating estimates and generating $142 million in revenue despite a 41.1% decrease in quarterly revenue compared to the previous year.

Northwest & Ethical Investments L.P. lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 48.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 22,462 shares of the company's stock after selling 21,004 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Moderna were worth $637,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Deutsche Bank AG lifted its position in shares of Moderna by 54.7% during the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock valued at $78,756,000 after acquiring an additional 669,614 shares during the last quarter. Tang Capital Management LLC purchased a new stake in shares of Moderna in the fourth quarter valued at $12,474,000. Bank of New York Mellon Corp lifted its holdings in shares of Moderna by 1.8% in the first quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock valued at $54,382,000 after purchasing an additional 34,034 shares in the last quarter. Wealthfront Advisers LLC lifted its holdings in shares of Moderna by 143.3% in the first quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock valued at $879,000 after purchasing an additional 18,268 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock valued at $74,557,000 after purchasing an additional 285,662 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research analyst reports. Leerink Partners reduced their target price on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a report on Friday. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday, August 1st. UBS Group reduced their target price on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Cowen initiated coverage on Moderna in a report on Sunday, July 13th. They issued a "hold" rating for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $42.88.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.90 during mid-day trading on Friday, reaching $27.12. 9,158,832 shares of the company traded hands, compared to its average volume of 8,197,467. The company's fifty day moving average is $29.18 and its two-hundred day moving average is $29.12. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $84.28. The stock has a market cap of $10.55 billion, a PE ratio of -3.60 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same period in the previous year, the company earned ($3.33) EPS. The company's revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.